Study cohorts’ age, therapy, clinical, and laboratory data.
| Variables | Values |
|---|---|
| Age, yrs, median (min–max) | |
| HC, at study entrance, n = 20 | 16.0 (15.5–20.9) |
| cSLE, n = 17 | |
| At diagnosis | 15.5 (6.8–17.2) |
| At study entrance | 18.0 (8.8–21.2) |
| Therapy, n (%) | |
| Antimalarials | 12 (71) |
| Corticosteroids | 10 (59) |
| Immunosuppressives | 7 (41) |
| Hypertension drugs | 4 (24) |
| Nonsteroidal antiinflammatory drugs | 2 (12) |
| Anticoagulants | 2 (12) |
| Antipsychotics | 1 (6) |
| Anti-epileptic drugs | 1 (6) |
| Biologics | – |
| Without therapy | 2 (12) |
| Laboratory and clinical signs, n (%) | |
| Low complement | 8 (47) |
| Reduced activation of classic pathway | 6 (35) |
| Low concentration of C3 | 5 (29) |
| Low concentration of C4 | 3 (18) |
| Anti-dsDNA antibodies | 4 (24) |
| Proteinuria | 3 (18) |
| Pyuria | 2 (12) |
| Arthritis | 2 (12) |
| Seizures | 1 (6) |
| Psychosis | 1 (6) |
| Headache | 1 (6) |
| Hematuria | 1 (6) |
| New rash | 1 (6) |
| Pleural effusion | 1 (6) |
| Fever | 1 (6) |
| Leukopenia | 1 (6) |
| Disease activity, n (%) | |
| SLEDAI-2K, median (min–max) | 5.1 (0–16) |
| SLEDAI-2K: 0 | 5 (29) |
| SLEDAI-2K: 1–5 | 7 (41) |
| SLEDAI-2K: ≥ 6 | 5 (29) |
cSLE: childhood-onset systemic lupus erythematosus; HC: healthy controls; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.